{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:40:44Z","timestamp":1784770844380,"version":"3.55.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.jacl.2014.02.012","type":"journal-article","created":{"date-parts":[[2014,4,29]],"date-time":"2014-04-29T08:16:57Z","timestamp":1398759417000},"page":"S17-S29","source":"Crossref","is-referenced-by-count":101,"special_numbering":"S","title":["An assessment by the Statin Diabetes Safety Task Force: 2014 update"],"prefix":"10.1016","volume":"8","author":[{"given":"Kevin C.","family":"Maki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Ridker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Virgil","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Grundy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2014.02.012_bib1","article-title":"2013 ACC\/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines [e-pub ahead of print]","author":"Stone","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2014.02.012_bib2","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2014.02.012_bib3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2014.02.012_bib4","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2014.02.012_bib5","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jacc.2004.07.001","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines","volume":"44","author":"Grundy","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2014.02.012_bib6","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jacl.2013.10.001","article-title":"An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia","volume":"7","author":"Grundy","year":"2013","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2014.02.012_bib7","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2014.02.012_bib8","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jacl.2014.02.012_bib9","first-page":"CD004816","article-title":"Statins for the primary prevention of cardiovascular disease","author":"Taylor","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacl.2014.02.012_bib10","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2014.02.012_bib11","unstructured":"Astra Zeneca. Clinical briefing document - Endocrine and Metabolic Drugs Advisory Committee meeting for rosuvastatin (Crestor). Available at: http:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/endocrinologicandmetabolicdrugsadvisorycommittee\/ucm193831.pdf. Accessed November 5,\u00a02013."},{"key":"10.1016\/j.jacl.2014.02.012_bib12","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.2337\/dc09-0738","article-title":"Statin therapy and risk of developing type 2 diabetes: a meta-analysis","volume":"32","author":"Rajpathak","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2014.02.012_bib13","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2014.02.012_bib14","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2014.02.012_bib15","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.jacc.2010.10.047","article-title":"Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials","volume":"57","author":"Waters","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2014.02.012_bib16","unstructured":"Food and Drug Administration. FDA drug safety communication: important safety label changes to cholesterol lowering statin drugs. Available at: http:\/\/www.fda.gov\/drugs\/drugsafety\/ucm293101.htm. Accessed November 6,\u00a02013."},{"key":"10.1016\/j.jacl.2014.02.012_bib17","unstructured":"The National Lipid Association. FDA changes label on statin drugs. Available at: https:\/\/www.lipid.org\/communications\/news\/other\/fda_changes_label_on_statin_drugs. Accessed November 5,\u00a02013."},{"key":"10.1016\/j.jacl.2014.02.012_bib18","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jacc.2012.09.042","article-title":"Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes","volume":"61","author":"Waters","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2014.02.012_bib19","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2014.02.012_bib20","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","article-title":"Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial","volume":"380","author":"Ridker","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2014.02.012_bib21","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2014.02.012_bib22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2014.02.012_bib23","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2014.02.012_bib24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00125-008-1179-5","article-title":"Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial","volume":"52","author":"Holman","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacl.2014.02.012_bib25","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1517\/14656566.2013.810210","article-title":"Statin therapy on glycaemic control in type 2 diabetes: a meta-analysis","volume":"14","author":"Zhou","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jacl.2014.02.012_bib26","article-title":"2013 ACC\/AHA Guideline on the Assessment of Cardiovascular Risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines [e-pub ahead of print]","author":"Goff","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2014.02.012_bib27","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2014.02.012_bib28","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1016\/S0140-6736(12)60283-9","article-title":"Prediabetes: a high-risk state for diabetes development","volume":"379","author":"Tabak","year":"2012","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.jacl.2014.02.012_bib29","first-page":"S14","article-title":"Standards of medical care in diabetes\u20132014","volume":"37","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2014.02.012_bib30","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"Defronzo","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.jacl.2014.02.012_bib31","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2337\/diabetes.50.4.905","article-title":"Measurements of renal glucose release","volume":"50","author":"Gerich","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.jacl.2014.02.012_bib32","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.diabres.2009.10.008","article-title":"Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis","volume":"87","author":"Baker","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jacl.2014.02.012_bib33","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.amjcard.2004.09.005","article-title":"Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia","volume":"95","author":"Lamendola","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2014.02.012_bib34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4137\/CMED.S7591","article-title":"Rosuvastatin and atorvastatin: comparative effects on glucose metabolism in non-diabetic patients with dyslipidaemia","volume":"5","author":"Abbas","year":"2012","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"10.1016\/j.jacl.2014.02.012_bib35","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.2337\/dc11-2251","article-title":"Statin intake is associated with decreased insulin sensitivity during cardiac surgery","volume":"35","author":"Sato","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2014.02.012_bib36","doi-asserted-by":"crossref","first-page":"E15","DOI":"10.1152\/ajpendo.00645.2007","article-title":"Current approaches for assessing insulin sensitivity and resistance in\u00a0vivo: advantages, limitations, and appropriate usage","volume":"294","author":"Muniyappa","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.jacl.2014.02.012_bib37","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S1262-3636(08)74602-0","article-title":"How to measure hepatic insulin resistance?","volume":"34","author":"Choukem","year":"2008","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.jacl.2014.02.012_bib38","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/HCO.0b013e3283470359","article-title":"Are statins diabetogenic?","volume":"26","author":"Sampson","year":"2011","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.jacl.2014.02.012_bib39","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.2174\/1381612811319270014","article-title":"Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance","volume":"19","author":"Banach","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jacl.2014.02.012_bib40","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s11892-013-0368-x","article-title":"Do statins cause diabetes?","volume":"13","author":"Goldstein","year":"2013","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.jacl.2014.02.012_bib41","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/01.hjh.0000160198.05416.72","article-title":"Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes","volume":"23","author":"Jandeleit-Dahm","year":"2005","journal-title":"J Hypertens"},{"key":"10.1016\/j.jacl.2014.02.012_bib42","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","article-title":"Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis","volume":"369","author":"Elliott","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2014.02.012_bib43","doi-asserted-by":"crossref","first-page":"e4624","DOI":"10.1136\/bmj.e4624","article-title":"Risk identification and interventions to prevent type 2 diabetes in adults at high risk: summary of NICE guidance","volume":"345","author":"Chatterton","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2014.02.012_bib44","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s00125-012-2715-x","article-title":"The link between family history and risk of type 2 diabetes is not explained by anthropometric, lifestyle or genetic risk factors: the EPIC-InterAct study","volume":"56","author":"InterAct Consortium","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacl.2014.02.012_bib45","series-title":"The DASH Diet Weight Loss Solution: 2 Weeks to Drop Pounds, Boost Metabolism, and Get Healthy (A DASH Diet Book)","author":"Heller","year":"2012"},{"key":"10.1016\/j.jacl.2014.02.012_bib46","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.2337\/dc11-9998","article-title":"Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus","volume":"34","author":"Sacks","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2014.02.012_bib47","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/dmrr.2260","article-title":"Prevalence of diabetes mellitus secondary to pancreatic diseases (type 3c)","volume":"28","author":"Ewald","year":"2012","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.jacl.2014.02.012_bib48","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1007\/s00125-011-2204-7","article-title":"Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol","volume":"54","author":"Lim","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacl.2014.02.012_bib49","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/dme.12039","article-title":"Banting Memorial lecture 2012: reversing the twin cycles of type 2 diabetes","volume":"30","author":"Taylor","year":"2013","journal-title":"Diabet Med"},{"issue":"Suppl 2","key":"10.1016\/j.jacl.2014.02.012_bib50","doi-asserted-by":"crossref","first-page":"S202","DOI":"10.2337\/dc11-s221","article-title":"Type 2 diabetes can be prevented with early pharmacological intervention","volume":"34","author":"DeFronzo","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2014.02.012_bib51","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc10-2415","article-title":"Benefits of modest weight loss\u00a0in improving cardiovascular risk factors in overweight and obese\u00a0individuals with type 2 diabetes","volume":"34","author":"Wing","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2014.02.012_bib52","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/jgs.12271","article-title":"Intensive weight loss intervention in older individuals: results from the Action for Health in Diabetes Type 2 diabetes mellitus trial","volume":"61","author":"Espeland","year":"2013","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jacl.2014.02.012_bib53","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2014.02.012_bib54","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1096\/fj.03-0839rev","article-title":"Modulatory effects of HMG-CoA reductase\u00a0inhibitors in diabetic microangiopathy","volume":"18","author":"Danesh","year":"2004","journal-title":"FASEB J"},{"key":"10.1016\/j.jacl.2014.02.012_bib55","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2174\/157016106777698388","article-title":"Statins for diabetic cardiovascular complications","volume":"4","author":"Ludwig","year":"2006","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.jacl.2014.02.012_bib56","doi-asserted-by":"crossref","first-page":"614","DOI":"10.2337\/diacare.20.4.614","article-title":"Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)","volume":"20","author":"Pyorala","year":"1997","journal-title":"Diabetes Care"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287414000749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287414000749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T23:48:56Z","timestamp":1565394536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287414000749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S1933287414000749"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2014.02.012","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}